Last reviewed 2026-04-20 · How we verify

TALZENNA capsule (talzenna-capsule)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anaemia
• Fatigue
• Nausea
• Headache
• Neutropenia
• Alopecia
• Vomiting
• Diarrhoea
• Back pain
• Decreased appetite
• Constipation
• Cough

Key clinical trials

• A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
• A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
• Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial (PHASE2)
• Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
• Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (PHASE2)
• Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC (PHASE1)
• Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency (PHASE2)
• FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.